Sudo Bio

   /   About   /    Team

Leaders committed to life-changing therapeutics

Sudo Biosciences leadership brings deep expertise to small molecule development in neurological and immune-mediated inflammatory conditions.

Jump to:

Sudo Team Board of Directors Investors

Sudo Team

Filter by:

Scott Byrd

Chief Executive Officer

Ian Mills, BM, BCh, DM

Chief Medical Officer

Gordon McMurray, PhD

Chief Development Officer

Imran Babar, PhD

Chief Business & Financial Officer

Paul Bavier, J.D.

Chief Legal Officer

David Hennings, PhD

Senior Vice President, Chemistry, Manufacturing and Controls

Anjali Pandey, PhD

Senior Vice President, Medicinal Chemistry

Marsilio Adriani

Director, Translational Biology

Vassilios Aslanis, PharmD, MSc

Vice President, Clinical Pharmacology

Rachel Eccles, DPhil

Vice President, Translational Pharmacology

Mark Evans, PhD

Neuropharmacology

Sally Fillingham

Clinical Trial Administration

Roy Gray

Vice President, Non-Clinical Development

Anitha Jeyanthan

R&D Project Management

Jack Kempster

Accountant

Sarah Loughrey-Jennings

Clinical Trial Management

Cliona MacSweeney, PhD

Head of Translational Medicine

Kelly Munro, PhD

Clinical Pharmacology

Matt Nelan, FCCA

Finance

Peadar O’Donohoe, MBChB, DPhil

Vice President, Clinical Development

Waylon Parham, CPA

Vice President, Finance & Controller

Kejal Patel, MSc

Vice President, Clinical Operations

Zainib Shabir

Clinical Trial Management

Fenella Smith

Executive Assistant

Gerry Thomas, PhD

Head of R&D Project Management

Terrie Walker-Smith

Clinical Trial Management

Board of Directors

Scott Byrd

Director

Edd Fleming, MD

Director

Shinichiro Fuse, PhD

Director

Chris Gagliardi, PhD

Director

Dave Johnson

Director

Dan Estes, PhD

Director

Investors

Partners in life science innovation